ALK and neuroblastoma: In this study, we have globally analyzed the effect of Crizotinib treatment on phosphoproteome changes in three representative neuroblastoma cell lines, NB1643, NB1, and SH-SY5Y, which harbor R1275 mutated, amplified, and F1174 mutated ALK, respectively [15].